Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here?

Jazz Pharmaceuticals (JAZZ) remains in focus on Tuesday morning after President Donald Trump demanded that the DOJ proceed quickly to reclassify cannabis as a Schedule III drug. 

The company spent $7.2 billion to acquire GW Pharmaceuticals in 2021 that added Epidiolex to its portfolio, an FDA-approved cannabidiol-based prescription medicine used to treat severe forms of epilepsy. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.